A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2018
At a glance
- Drugs LYS-006 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Oct 2018 Planned End Date changed from 17 Sep 2019 to 18 Oct 2019.
- 10 Oct 2018 Planned primary completion date changed from 17 Sep 2019 to 18 Oct 2019.
- 10 Oct 2018 Status changed from not yet recruiting to recruiting.